{"name":"Azienda Ospedaliera di Perugia","slug":"azienda-ospedaliera-di-perugia","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Aspirin plus clopidogrel","genericName":"Aspirin plus clopidogrel","slug":"aspirin-plus-clopidogrel","indication":"Other","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Placebo, Palonosetron, Dexamethasone","genericName":"Placebo, Palonosetron, Dexamethasone","slug":"placebo-palonosetron-dexamethasone","indication":"Prevention of chemotherapy-induced nausea and vomiting (CINV) in cancer patients receiving highly emetogenic chemotherapy","status":"phase_3"}]}],"pipeline":[{"name":"Aspirin plus clopidogrel","genericName":"Aspirin plus clopidogrel","slug":"aspirin-plus-clopidogrel","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo, Palonosetron, Dexamethasone","genericName":"Placebo, Palonosetron, Dexamethasone","slug":"placebo-palonosetron-dexamethasone","phase":"phase_3","mechanism":"This is a combination regimen using palonosetron (a 5-HT3 antagonist) and dexamethasone (a corticosteroid) to prevent chemotherapy-induced nausea and vomiting, with placebo as a control arm.","indications":["Prevention of chemotherapy-induced nausea and vomiting (CINV) in cancer patients receiving highly emetogenic chemotherapy"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTFBnRXFNczVBYy0wd3dGXzFrOHRZUHI1Vi1wZE0wWmpTaFVuNmx3TVdoRzYzWV82VTNFOXYwZkhHWHNTR0k5QWFldklHemMyWXlfbldwVXJ3WVFUeURveEd2R2lBdWRleVg3TFE?oc=5","date":"2024-10-29","type":"pipeline","source":"Wiley Online Library","summary":"Real-World Evidence of Crizanlizumab Showing Reductions in Vaso-Occlusive Crises and Opioid Usage in Sickle Cell Disease - Wiley Online Library","headline":"Real-World Evidence of Crizanlizumab Showing Reductions in Vaso-Occlusive Crises and Opioid Usage in Sickle Cell Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE9VaFZkUHd6N1JVSDFRdXloLVdKTGlITXVtcXpWV3BOWnYyVjZkZTlLRzJuOHR2REgxOS1oRklNbGFoVWhVUkF0dlVVcGxvUFJ3d2dzMU9ycjJzelRGeWgzVmY1Q3RLdDYwbk1R?oc=5","date":"2023-12-01","type":"trial","source":"Wiley Online Library","summary":"Pharmacoutilization and adherence to sacubitril/valsartan in real world: the REAL.IT study in HFrEF - Wiley Online Library","headline":"Pharmacoutilization and adherence to sacubitril/valsartan in real world: the REAL.IT study in HFrEF","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":1,"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}